Overview

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Metformin
Sitagliptin Phosphate
Vildagliptin